← Eichor
Study identifier: NCT07490353 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects

Condition: Depression - Major Depressive Disorder · Anhedonia  ·  Sponsor: Medical University of Vienna

PhasePhase 1
Planned participants85
Who can joinAll sexes, 18 Years to 55 Years
Healthy volunteersYes

About this study

The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are: Primary Objectives 1. Systematically categorize prohedonic effects (antianhedonic effects in patients with anhedonia in depression, increase in well-being in all participants). 2. Test effects of psilocybin on brain network complexity measures during the hedonic experience using fMRI as a correlate for prohedonic (anti-anhedonic and well-being increasing) effects. 3. Elucidate relevance of the psychedelic experience to these effects (clinical, behavioral, and imaging) in a pharmacological challenge using the 5-HT2A/D2 antagonist risperidone and extensive characterization of the psychedelic experience. Secondary Objectives 4. Test the differential effects of the psychedelic experience on fMRI paradigms measuring symptoms shown to be altered in anhedonia, more specifically reward processing and sexual arousal. 5. Test the relevance of neuroplasticity (BDNF) and inflammatory parameters to anti-anhedonic, well-being promoting, and brain network dynamic complexity effects. 6. Test the effects of the psychedelic experience on BDNF and inflammatory parameters. Researchers will compare the effects of psilocybin in two separate sessions (one with psilocybin alone, one with co-administration of risperidone) in both patients with depression and anhedonia and healthy control participants. Partici…

This description comes directly from the study's public registry record.

Talk to the study team

Marie Spies, Priv.-Doz. DDr.  ·  +43 1 40400  ·  marie.spies@meduniwien.ac.at

Clemens Schmidt, MD  ·  +43 1 40400  ·  clemens.schmidt@meduniwien.ac.at

Always discuss trial participation with your own doctor first.

Locations (1)

Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General PsychiatryVienna, State of Vienna, AustriaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07490353